NervGen Pharma (NGEN)
Develops NVG-291 for spinal-cord injury.
Something off on this page? Send us feedback.
NVG-291 is a neuroreparative peptide in clinical development for spinal-cord injury, alongside next-generation candidate NVG-300. A Vancouver-based, pre-commercial developer, NervGen relies on licensed Case Western science, clinical progress and capital formation.
Advances NVG-291, a subcutaneously administered neuroreparative peptide for spinal-cord injury. The active program includes the CONNECT SCI study, a planned RESTORE registrational study in chronic tetraplegia, and next-generation candidate NVG-300.
Operates as a Vancouver-based clinical-stage developer built around an exclusive worldwide license to patented Case Western Reserve University technology. That license covers research, development and commercialization for spinal-cord injury and other nerve-damage conditions.
Remains clinical-stage rather than commercial, with no approved product or product revenue. The business depends on clinical development, regulatory milestones under the license, and capital raised to advance NVG-291 and corporate operations.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $61.7M · Total debt $0 · Total assets $64.1M · Shareholders' equity $12.3M
- Revenue
- $0
- Operating income
- −$8.9M
- Net income
- −$21.3M
Reported in CAD, converted at the latest exchange rate
No dividends on record.
| Institutions | 14.59% | 11.99M shares | |
|---|---|---|---|
| 65 holders · as of Jun 30, 2026 | |||
| Other | 85.41% | 70.20M shares | |
| remainder | |||
82.19M company shares as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Empery Asset Management, LPInstitution | 4.87% | 4.00M | as of Jun 30, 2026 |
Rock Springs Capital Management LPInstitution | 1.47% | 1.21M | as of Jun 30, 2026 |
Dafna Capital Management LLCInstitution | 1.28% | 1.05M | as of Jun 30, 2026 |
Ghisallo Capital Management LLCInstitution | 1.22% | 1.00M | as of Jun 30, 2026 |
Armistice Capital, LLCInstitution | 0.82% | 678,000 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Lineage Cell Therapeutics
Cell-replacement program for subacute and chronic spinal-cord injury
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NervGen Pharma | $2.03 | −1.69% | $169.7M | — | — | — | — |
| Lineage Cell Therapeutics | $0.9677 | −6.95% | $259.3M | — | — | 19.8 | −61.3% |
| Median | — | — | 19.8 | −61.3% |